Advertisement

Morbid Obesity

  • Minna Ferrari Schleu
  • Karyne Freitas Barbosa
Chapter
  • 34 Downloads

Abstract

Obesity is a chronic disease with increasing prevalence worldwide. Morbid obesity is defined when BMI is ≥40 kg/m2. Etiology of obesity in this subgroup is more frequently associated with secondary causes and genetic syndromes. There is a positive correlation between BMI and complications. As BMI increases, comorbidities are more prevalent and mortality rises. Weight loss is related to improvement of diabetes, hypertension, lipid levels, and other complications. Lifestyle intervention with a healthy diet, physical activity, and behavioral changes must be encouraged. These interventions have not been associated with good and sustained results in morbidly obese individuals. Pharmacological treatment is usually necessary to reach at least 5% reduction of initial body weight, which is suggested to be related to a reduction of mortality and improvement of quality of life. New drugs have recently been developed, and treatment must be individualized, based on dietary patterns and lifestyle. Some drugs are more effective for this subgroup of patients. Bariatric surgery is the most effective intervention as it provides a greater and sustained weight loss and is reserved for those patients who fail to these clinical strategies.

Keywords

Obesity Morbid obesity Complications Comorbidities Lifestyle intervention Treatment Drugs Bariatric surgery 

References

  1. 1.
    Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr [Internet]. 2012;10(1):22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23167948.CrossRefGoogle Scholar
  2. 2.
    Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9??1 million participants. Lancet. 2011;377(9765):557–67.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–209Google Scholar
  4. 4.
    Europe PMC Funders Group. Global, regional and national prevalence of overweight and obesity in children and adults 1980–2013: a systematic analysis. Lancet. 2014;384(9945):766–81.CrossRefGoogle Scholar
  5. 5.
    National Institutes of Health. Weight management techniques. Pract Guid Identification, Eval Treat Overweight Obes Adults [Internet]. 2000;26–7. Available from: http://www.who.int/nutrition/topics/FFA_summary_rec_conclusion.pdf.
  6. 6.
    Manson J, Willett W, Stampfer M, Colditz G, Hunter DW, Hankinson S, et al. Body weight and mortality among women. N Engl J Med. 1995;333(11):677–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Sturm R, Ph D, Economist S. Morbid Obesity Rates Continue to Rise Rapidly in the US. Int J Obes. 2013;37(6):889–91.CrossRefGoogle Scholar
  8. 8.
    Abeso. Obesidade: Diagnóstico e Tratamento de Crianças e Adolescentes. Diretrizes Brasileiras de Obesidade 2009/2010/ABESO. 2009. 63–70 p.Google Scholar
  9. 9.
    WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser [Internet]. 2000;894:i–xii, 1–253. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11234459.Google Scholar
  10. 10.
    Rodrigues AM, Suplicy HL, Radominski RB, Endocrinologia SS De. Implicações na Gênese da Obesidade. 47(Imc).Google Scholar
  11. 11.
    Coutinho W. Etiologia da obesidade. Abeso [Internet]. 2007;7(30):14. Available from: http://www.abeso.org.br/pdf/EtiologiaeFisiopatologia-Walmir Coutinho.pdf.Google Scholar
  12. 12.
    van den Bree MBM, Eaves LJ, Dwyer JT. Genetic and environmental influences on eating patterns of twins aged greater than or equals to 50 y. Am J Clin Nutr [Internet]. 1999;70(4):456–65. Available from: http://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=jlh&AN=2000000362&site=ehost-live.CrossRefGoogle Scholar
  13. 13.
    Xia Q, Grant SFA. The genetics of human obesity. Ann N Y Acad Sci. 2013;1281(1):178–90.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet [Internet]. 2009;17(1):3–13. Available from:  https://doi.org/10.1038/ejhg.2008.165PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet [Internet]. 2013;21(1):8–13. Available from: http://www.nature.com/ejhg/journal/v21/n1/full/ejhg2012115a.html#bib39.CrossRefGoogle Scholar
  16. 16.
    Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med [Internet]. 2003;348:1085–95. Available from: internal-pdf://3543829267/MR4GENE.pdf\n http://www.ncbi.nlm.nih.gov/pubmed/12646665.CrossRefGoogle Scholar
  17. 17.
    Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Farooqi S, Rau H, Whitehead J, O’Rahilly S. Ob gene mutations and human obesity. Proc Nutr Soc. 1998;57(3):471–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356(3):237–47.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–105.PubMedCrossRefGoogle Scholar
  21. 21.
    Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121(6):21–33.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Barton M. Childhood obesity: a life-long health risk. Acta Pharmacol Sin. 2012;33(2):189–93.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138(11):1240–4.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Stampfer MJ, Maclure KM, Colditz GA, Manson JE, Willett WC. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr. 1992;55(3):652–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG. The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metab Clin Exp. 2013;62:457–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Haffner SM. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord. 2000;24(Suppl 2(2)):S56–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Weaver JU, Holly JM, Kopelman PG, Noonan K, Giadom CG, White N, et al. Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. Clin Endocrinol. 1990;33(3):415–22.CrossRefGoogle Scholar
  31. 31.
    Lash MM, Armstrong A. Impact of obesity on women’s health. Fertil Steril. 2009;91(5):1712–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Metwally M, Li TC, Ledger WL. The impact of obesity on female reproductive function. Obes Rev. 2007;8(6):515–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int J Obes. 2010;34(3):407–19.CrossRefGoogle Scholar
  34. 34.
    Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression and anxiety among US adults: associations with body mass index. Int J Obes. 2009;33(2):257–66.CrossRefGoogle Scholar
  35. 35.
    Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–65.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care. 2013;36(SUPPL.2):233–9.CrossRefGoogle Scholar
  37. 37.
    Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med. 2005;353:2197–9.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137:711–9.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg. 2003;13(5):676–83.PubMedCrossRefGoogle Scholar
  41. 41.
    McClean KM, Kee F, Young IS, Elborn JS. Obesity and the lung: 1. Epidemiology 1. Thorax. 2008;63(1468–3296 (Electronic)):649–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J. 2006;13:203–10.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Sebastian JC. Respiratory physiology and pulmonary complications in obesity. Best Pract Res Clin Endocrinol Metab. 2013;27:157–61.PubMedCrossRefGoogle Scholar
  44. 44.
    Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function 2. J Appl Physiol. 2010;108(1522–1601 (Electronic)):206–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Schunemann HJ, Dorn J, Grant BJB, Winkelstein WJ, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-Year follow-up of the Buffalo Health Study. Chest. 2000;118(3):656–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Yumuk V, Frühbeck G, Oppert JM, Woodward E, Toplak H. An EASO position statement on multidisciplinary obesity management in adults. Obes Facts. 2014;7(2):96–101.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Miller NH, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk. Circulation. 2014;129(25 suppl 2):S76–99.PubMedCrossRefGoogle Scholar
  48. 48.
    Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Jensen MD, Ryan DH, Apovian CM, Loria CM, Ard JD, Millen BE, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2013;1:1–70.Google Scholar
  50. 50.
    (UK) NCGC. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults: partial update of CG43. National Institute for Health and Clinical Excellence: Guidance. 2014.Google Scholar
  51. 51.
    Wadden TA. Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study. Obesity. 2014;22(1):5–13.CrossRefGoogle Scholar
  52. 52.
    Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the look AHEAD trial. Diabetes Care. 2011;34(10):2152–7.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Gilden Tsai A, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity. 2006;14(8):1283–93.CrossRefGoogle Scholar
  54. 54.
    Allison DB, Gadde KM, Timothy Garvey W, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obes (SilverSping, Md). 2012;20(2):330–42.CrossRefGoogle Scholar
  55. 55.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden C. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine. Am J Clin Nutr. 2012;95(2):297–308.PubMedCrossRefGoogle Scholar
  57. 57.
    Macdaniels JS, Schwartz TL. Effectiveness, tolerability and practical application of the newer generation anti-obesity medications. Drugs Context. 2016;5:11.CrossRefGoogle Scholar
  58. 58.
    BELVIQ® Prescribing Information. 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf.
  59. 59.
    Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med [Internet]. 2010;363(3):245–56. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0909809\npapers2://publication/doi/10.1056/NEJMoa0909809.PubMedCrossRefGoogle Scholar
  60. 60.
    Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–43.PubMedCrossRefGoogle Scholar
  61. 61.
    Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet [Internet]. 2016;6736(16):1–10. Available from:  https://doi.org/10.1016/S0140-6736(16)00271-3.CrossRefGoogle Scholar
  62. 62.
    Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17:1021–32.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Jarl S, Mark N. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27(1):155–61.CrossRefGoogle Scholar
  64. 64.
    Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med [Internet]. 2015;373(1):11–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26132939.CrossRefGoogle Scholar
  65. 65.
    Kim SH, Chun HJ, Choi HS, Kim ES, Keum B, Jeen YT. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016;22:5495–504.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Kumar N. Weight loss endoscopy: Development, applications, and current status. World J Gastroenterol. 2016;22(31):7069–79.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Minna Ferrari Schleu
    • 1
  • Karyne Freitas Barbosa
    • 2
  1. 1.EndocrinologyClínica MettaSalvadorBrazil
  2. 2.Endocrinology DivisionSão RafaelSalvadorBrazil

Personalised recommendations